Prognostic value of baseline neutrophil/lymphocyte ratio in HER2-positive metastatic breast cancer: exploratory analysis of data from the CLEOPATRA trial

Prognostic value of baseline neutrophil/lymphocyte ratio in HER2-positive metastatic breast cancer: exploratory analysis of data from the CLEOPATRA trial

Abstract Purpose This study aimed to evaluate the prognostic role of the baseline neutrophil/lymphocyte ratio (NLR) in HER2-positive metastatic breast cancer (MBC) patients treated with trastuzumab/pertuzumab. Experimental design Data from 780 patients from the CLEOPATRA trial and 248 local patients...

Descrizione completa

Dettagli Bibliografici
Autori principali: Nianhua Ding, Jian Pang, Xuan Liu, Xiongbin He, Wei Zhou, Haiqing Xie, Jianqi Feng, Guo Wang, Jie Tang, Jing Cao, Liying He, Yingjian He, Shouman Wang, Zhi Xiao
Natura: Articolo
Lingua:English
Pubblicazione: BMC 2024-01-01
Serie:Breast Cancer Research
Soggetti:
Neutrophil/lymphocyte ratio
HER2-positive
Metastatic breast cancer
Trastuzumab/pertuzumab
Prognostic value
Accesso online:https://doi.org/10.1186/s13058-023-01761-x

Accesso online

https://doi.org/10.1186/s13058-023-01761-x

Documenti analoghi